Drugs / Somatotropin
Somatotropin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01576861 | Jan 2007 → Mar 2011 | heart failure, pituitary deficiency | Federico II University | Completed | No outcome recorded |
| Phase 2 | NCT00591760 | Dec 2004 → Nov 2007 | ischemic disease, pituitary deficiency, systolic heart failure | Federico II University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05602090 | Feb 2022 → Sep 2023 | ovarian dysfunction | Beni-Suef University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00458263 | Apr 2006 → May 2011 | isolated short stature | Rabin Medical Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01367834 | May 2010 → May 2014 | Turner syndrome | Rebecca Knickmeyer Santelli, PhD | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00533221 Comparator | Oct 2007 → Feb 2010 | spinal muscular atrophy | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 3 | NCT02736591 Comparator | Jun 2016 → Apr 2017 | infertility disorder | Cairo University | Unknown | No outcome recorded |
Press releases naming this drug 10 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somatotropin | “Growth hormone (Somatotropin, Sedico, Egypt) 4 IU on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering.” NCT02736591 ↗ |
| Known as | Growth hormone | “Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle.” NCT05602090 ↗1“Growth hormone (Somatotropin, Sedico, Egypt) 4 IU on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering.” NCT02736591 ↗ |
| Known as | growth hormone recombinant human | “Somatotropin growth hormone recombinant human” NCT00458263 ↗ |
| Known as | recombinant Human Growth Hormone | “Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day” NCT01576861 ↗ |
| Action | Restore | “correction of growth hormone (GH) deficiency with GH replacement therapy” NCT00591760 ↗ |
| Modality | Protein / enzyme biologic | “Somatotropin growth hormone recombinant human” NCT00458263 ↗ |
| Route | Subcutaneous | “daily Sub Cutaneous injections” NCT00458263 ↗ |